Lindsay Fischer

Articles

Similar Total Scores Are Observed With GCLQ and LELSQ in Assessing Patients With Endometrial Cancer for Lymphedema

March 26th 2023

The gynecological cancer lymphedema questionnaire and the lower extremity lymphedema screening questionnaire showed moderate to substantial agreement across different cutoff points.

New Approvals Continue to Shift Treatment Landscape in Hematologic Malignancies

February 27th 2023

Kathryn Maples, PharmD, BCOP, discusses recent approvals, updated labeling, and drug removals across leukemia, lymphoma, and multiple myeloma.

Avelumab Efficacy Holds-Up In A Real-World Analysis of Patients With Locally Advanced, Metastatic Urothelial Carcinoma

February 20th 2023

The efficacy profile for avelumab in patients with locally advanced or metastatic urothelial carcinoma was consistent in a real-world setting with what had been reported in the phase 3 JAVELIN Bladder 100 trial.

Frontline Pola-R-CHP, CAR T-Cell Second-line Therapies Are Not Cost-effective in DLBCL

February 7th 2023

An economic analysis showed that neither polatuzumab vedotin-piiq added to standard of care chemotherapy nor CD19-directed chimeric antigen receptor T-cell therapy is likely to be the most cost-effective for patients with diffuse large B-cell lymphoma.

Both Gastric and Breast HER2 Scoring Algorithms Applicable in mCRC Testing

January 23rd 2023

The high concordance rate between gastric and breast cancer HER2 scoring algorithms suggest that either may be used in the metastatic colorectal cancer setting.

LEAP-002 HRQOL Analysis Shows Comparable Scores with Pembrolizumab/Lenvatinib Vs Lenvatinib/Placebo in HCC

January 20th 2023

In the first-line treatment of patients with advanced hepatocellular carcinoma, a combination of pembrolizumab plus lenvatinib yielded similar health-related quality of life scores as lenvatinib plus placebo, according to a HRQOL analysis of the phase 3 LEAP-002 study.

Adjuvant Pembrolizumab Improves QOL vs Ipilimumab or HDI in Resected Melanoma

January 10th 2023

Treatment with adjuvant pembrolizumab resulted in favorable quality-of-life outcomes vs high-dose interferon α 2b or ipilimumab in patients with resected melanoma at high risk for relapse.

Oxaliplatin Treatment Duration Potentially Linked With Incidence of Severe Neuropathy in Stage III Colon Cancer

January 9th 2023

Patients with stage III colon cancer who receive longer courses of adjuvant oxaliplatin, exercise for less than 9 hours per week, have diabetes, or have a higher body mass index could experience higher rates of severe oxaliplatin-induced peripheral neuropathy.

GRIFFIN Patient-Reported Outcomes Data Support Frontline Daratumumab-Quadruplet Therapy in Transplant Eligible, Newly Diagnosed, Multiple Myeloma

December 11th 2022

Daratumumab in addition to bortezomib, lenalidomide, and dexamethasone induction/consolidation therapy, as well as with lenalidomide maintenance, showcased a promising health-related quality of life benefit for patients with transplant eligible, newly diagnosed multiple myeloma.

Trastuzumab Deruxtecan, With or Without Endocrine Therapy, Shows Promising Responses in Operable HR+, HER2-Low Breast Cancer

December 7th 2022

Neoadjuvant treatment with trastuzumab deruxtecan showed promising responses in patients with early-stage breast cancer.

Extended Treatment Time With Bevacizumab Does Not Confer PFS Benefit in Ovarian Cancer

November 26th 2022

Increasing the duration of bevacizumab treatment in the frontline setting did not improve progression-free survival for patients with advanced ovarian cancer.

Forging a New Field

November 25th 2022

Almost single-handedly, Jennifer Temel, MD, defined a research field in medicine, creating a new focus on quality of life for patients and survivors.

Quality Improvement Project Shows Reduced Time From Diagnosis to NGS in Patients With NSCLC

November 21st 2022

The median time between pathologic diagnosis to next-generation sequencing was reduced in a quality improvement project for patients with newly diagnosed metastatic non–small cell lung cancer.

Emerging Therapies Prompt Nuanced AE Management in Kidney Cancer

November 6th 2022

Kiran Virdee, RN, BSN, CCRN-K, outlines the best practices for the management of adverse effects during the treatment of kidney cancer.

Encorafenib/Binimetinib Delivers Prolonged Survival in BRAF V600–Mutant Melanoma

October 21st 2022

The combination of encorafenib and binimetinib led to sustained improvements in progression-free survival and overall survival, without new safety signals in patients with BRAF V600–mutant melanoma, according to 5-year follow-up of the phase 3 COLUMBUS trial.

Letrozole Plus Abemaciclib Elicits Promising Responses in ER+ Endometrial Cancer

October 14th 2022

Dual inhibition with letrozole and abemaciclib displayed response and survival benefits in patients with recurrent estrogen receptor–positive endometrioid endometrial cancer.

Luspatercept Demonstrates Long-Term Anemia Benefit in Lower-Risk MDS

October 7th 2022

Luspatercept produced favorable safety and long-term efficacy in patients with untreated lower-risk myelodysplastic syndromes, irrespective of subtype.

Intensity-Modulated Radiation Therapy Decreases GI and Urinary Toxicity in Endometrial and Cervical Cancer

September 26th 2022

Intensity-modulated radiation therapy elicited durable efficacy and a favorable safety profile compared with conventional radiotherapy in patients with endometrial and cervical cancers who received postoperative pelvic radiation.

HRQOL Outcomes in TNBC Are Not Negatively Affected by Pembrolizumab

September 12th 2022

An analysis of patient-reported outcomes from the phase 2 KEYNOTE-522 trial demonstrated that pembrolizumab was not associated with effects on health-related quality of life in patients with triple-negative breast cancer.

Destiny-Breast04 Update Showcases QOL Benefit With Trastuzumab Deruxtecan for HR+, HER2-Low Breast Cancer

September 11th 2022

Trastuzumab deruxtecan demonstrated a promising quality-of-life benefit for patients with hormone receptor–positive, HER2-low metastatic breast cancer, according to a report on patient-reported outcomes from the pivotal DESTINY-Breast04 trial.